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thereby providing additional information on secondary care in England. This 
study aimed to generate more accurate resource use for the management of CLL 
and iNHL by using the THIN-HES database. Methods: First, a MEDLINE and UK 
Health Technology Appraisals (HTAs) reviews were undertaken to identify stud-
ies documenting the cost of previously-treated iNHL and CLL in the UK. Then, to 
collect patients health care resource use, THIN database linked to the HES dataset 
was analysed. Results: Three HTAs were identified as relevant, and cost esti-
mates relied on assumptions from clinical experts. Assumptions varied as TA193 
related to relapsed CLL assumed that health care visits were three times more 
frequent post-progression (3 consultations/month: £86) than pre-progression (1 
consultation/month: £28.67) while another, TA202, assumed a rather constant 
number of visits across the two health states (1 clinic visit per month: £121.11). 
Therefore, analyses of the THIN database linked to HES were undertaken, includ-
ing more than 1 000 patients. OPCS4 codes and READ codes in the HES and THIN 
databases respectively, were used to identify treatments prescribed and proce-
dures undertaken. Costs were estimated by applying unit costs from national 
references. ConClusions: To our knowledge, this analysis is the first retrospec-
tive observational study to assess the cost of managing previously-treated CLL 
and iNHL in the UK. This study will serve as an important resource in the health 
economic evaluation of emerging therapies. This method suggests a greater stand-
ardization of disease management costs across HTAs.
PRM36
A SySteMAtic Review of MethodS to ASSeSS the econoMic iMPAct of 
AiR Pollution
Conti S., Fornari C., Madotto F., Cesana G.
University of Milano - Bicocca, Monza, Italy
objeCtives: Despite the fact that short and long-term effects of the exposure to 
air pollution on health have been extensively analyzed, estimates of the health 
care economic impact of such effects are still limited. We therefore carried out a 
systematic review of the literature, with the aim of identifying the current major 
research focuses in the field and the topics that will need to be addressed in the 
future. Methods: We searched the electronic databases MEDLINE and EMBASE, 
in which we applied respectively the following algorithms: 1) “((“cost of illness” 
[MeSH Terms] OR “health care costs” [MeSH Terms] OR “health expenditures” [MeSH 
Terms]) AND “environmental pollution” [MeSH Terms]) OR (Pollution [Title/Abstract] 
AND (Expenditure [Title/Abstract] OR Expenditures [Title/Abstract] OR cost [Title/
Abstract] OR costs [Title/Abstract]) AND (health [Title/Abstract] OR health care [Title/
Abstract]))“; 2) “‘health care cost’/exp AND ‘pollution’/exp”. Searches were limited 
to article written in English and Italian, without any date restriction. Results: 
The initial selections identified 775 records in MEDLINE and 466 in EMBASE, 149 
of which were classified as relevant. They focused on a wide range of pollutants, 
including volatile organic compounds, nitrogen dioxide, pesticides, ozone, particu-
late matter and tobacco smoke. Most of the studies assessed the health impact of 
environmental pollutants using direct and indirect cost estimates acquired from 
literature, mainly relying on cost of illness methods; 27 papers used an individual 
direct health care costs approach, but they usually didn’t involve indirect costs in 
the final computations. Finally, only a few studies distinguished between short-term 
and long-term effect of air pollution. ConClusions: The results of our review iden-
tified two main topics that deserve further research: future health impact assess-
ments should integrate indirect costs estimates with information from the direct 
modeling of real-life health care costs; the short- and long-term economic impacts 
should be clearly separated.
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objeCtives: This analysis assessed the cost effectiveness of ipilimumab 3mg/
kg as first-line treatment for metastatic melanoma. As ipilimumab has an exist-
ing second-line recommendation, the decision problem is ipilimumab first-line 
followed by best supportive care (BSC), compared with Scottish clinical practice 
- dacarbazine or vemurafenib first-line followed by ipilimumab. Methods: In line 
with SMC requirements, an area under the curve model was built comparing first-
line ipilimumab, dacarbazine and vemurafenib. The model utilised progression, 
survival and utility data from CA184-024 for ipilimumab/dacarbazine and dacar-
bazine, survival data from MDX010-20 for ipilimumab second-line, and survival 
and progression data from BRIM-3 for vemurafenib. MDX010-20 and observational 
data, using the approved regimen, were tested within scenario analyses assessing 
the performance of ipilimumab 3mg/kg at first-line. 2013 costs were taken from 
Scottish or UK official sources. Results: Economic analysis, including patient 
access schemes for ipilimumab and vemurafenib, shows that ipilimumab first-
line followed by BSC is cost-effective versus dacarbazine first-line followed by 
ipilimumab (incremental costs: £10,502, incremental quality-adjusted life-years 
[QALYs]: 0.33, incremental cost-effectiveness ratio [ICER]: £31,481). Compared with 
ipilimumab first-line followed by BSC, the sequence vemurafenib first-line fol-
lowed by ipilimumab is associated with incremental QALYs (0.26) but also incre-
mental costs (£33,306), resulting in a not cost-effective cost/QALY trade-off (ICER 
= £126,482), i.e. ipilimumab first-line should be the preferred option. A scenario 
analysis that compared ipilimumab first-line with vemurafenib first-line alone 
resulted in ipilimumab being the dominant treatment option. Comprehensive 
sensitivity analyses identified survival parameters as having the largest impact 
on model results. Ipilimumab remained cost-effective at a threshold of £50,000 
per QALY gained against both comparators. ConClusions: First-line ipilimumab 
treatment for melanoma is cost-effective, and as a first-line option it would 
expand clinician choice, enabling selection of the most appropriate therapy for 
patients depending on their disease characteristics and BRAF mutation status.
Mauskopf et al. in 2005 and 2007. ConClusions: Based on the results we suggest the 
following definition for BIA: “A budget impact analysis is a form of health economic 
evaluation. Its purpose is to predict the financial consequences of the introduction 
or removal of an intervention from the current health care setting. Therefore BIA 
is a framework to synthesize the best available evidence. Rather than calculating 
a precise impact number it provides a valid model to the decision maker, enabling 
him to understand the relative effects of his decisions. The analysis is undertaken by 
modeling two scenarios where the reference scenario is the status quo and the second 
scenario a simulation of the decision to be made. The model parameters are chosen 
according to the framework requirement of the decision maker.”
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objeCtives: To explore patient characteristics, resource use and costs related to 
different episodes of care (EOC) in Finnish health care. EOC is a health problem 
needing testing, diagnosis, care or follow-up from its first presentation by the 
patient to health care until the completion of the last health care contact for 
it. Literature around costs of episodes (COE) is scarce. Methods: Primary and 
secondary care data was collected during the three months prospective, non-
randomized follow-up study (Effective Health Centre) using questionnaires and 
electronic health record. Setting included three primary health care practices in 
Pirkanmaa, Finland. 622 (41% of potential) patients were recruited during one 
week period. Patients that had doctor/nurse appointment on the recruiting day 
and agreed to participate were included. Patients visiting specialized health guid-
ance clinic for pregnant women, children and mothers were excluded. The main 
outcome measures were patient characteristics, resource use and costs classified 
based on the International Classification of Primary Care (ICPC-2) episode title 
codes. Resource use was valued with health care providers’ 2012 unit costs. Social 
Insurance Institution costs (e.g. outpatient drugs) were excluded. Results: On 
average, patient had 1.22 EOCs during the three months. Patient characteristics 
and resource use differed between the EOC-classes. Class L ‘Musculoskeletal’ had 
the highest number of episodes (17%). The most common (8%) single EOC was 
‘upper respiratory infection’. The mean COE was € 390 (SE € 61) and the median COE 
was € 165 (IQR € 118-289) during the three month follow-up. The most expensive 
class was K ‘Circulatory’, with a mean COE of € 910. The most expensive single COE 
(€ 32,546) was in the group K. The most expensive one percent of COEs summed up 
covered 36% of total COEs. ConClusions: Patient characteristics, resource use 
and costs differed between the ICPC-2 classes, which could be taken into account 
in evaluations, planning and pricing.
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objeCtives: In the last twenty years there has been an intense debate on how to 
value lost productivity in economic evaluations. According to the Washington panel, 
lost productivity influences health-related quality of life (HRQoL) and should thus 
be considered a health effect instead of a cost to avoid double counting. Until now 
empirical evidence on the inclusion of income loss when valuing health states is 
not decisive. We examine the relationship between three aspects of lost productiv-
ity (work-status, absenteeism and presenteeism) and patient or social valuation of 
health-related quality of life. Methods: Cross-sectional survey data from a total of 
830 respondents with a rheumatic disorder from four Western-European countries. 
Health-related quality of life was expressed in either the European societal utility 
using EQ-5D-3L or the patient valuation using EQ-VAS. Linear regression analyses 
were performed to examine the impact of work-status (four categories), absen-
teeism (absent from paid work during the past three months), and presenteeism 
(QQ method) on EQ-5D utilities and VAS scores taking demographic characteris-
tics and disease severity (duration, pain and restriction) into account. Results: 
The relationship between work-status, absenteeism or presenteeism and HRQoL 
is stronger for patient valuation than societal valuation. Compared to work-status 
and presenteeism is the relationship between absenteeism and HRQoL even less 
explicit. However, results for all measures of work are only marginal significant 
and negligible compared to the influence of restriction due to disease we studied.  
ConClusions: In four European countries, analyses among patients with a rheu-
matic disorder do not fully support the claim of the Washington panel that lost 
productivity has a significant relationship with HRQoL, and this is even more appar-
ent for absenteeism than for work-status and presenteeism. Therefore absenteeism 
should continue to be included in the costs and not in the QALY. Findings need to 
be confirmed in other disease areas.
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coSt of PReviouSly tReAted chRonic lyMPhocytic leukeMiA (cll) And 
indolent non-hodgkin’S lyMPhoMA (inhl) in the united kingdoM (uk)
Cognet M.1, Druais S.1, Gervais F.1, Gauthier A.1, Abrams K.R.2
1Amaris, London, UK, 2University of Leicester, Leicester, UK
objeCtives: Accurate cost data are required to inform cost-effectiveness assess-
ments of novel treatments in the UK for NICE appraisals. Up to now, levels of 
resource use to manage CLL and iNHL have mainly been based on clinical expert 
opinion. However, recently, two key primary care databases in the UK (THIN and 
CPRD) were linked with Hospital Episode Statistics (HES) at the patient level, 
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parameters that can be combined to produce suitable measures of cost (c) and clinical 
benefits (e) associated with an intervention. Within the Bayesian framework (which is 
the natural environment for BCEA), this amounts to estimating a posterior distribu-
tion for the pair (e, c). Health economic evaluations then proceed by computing some 
relevant summaries of the resulting decision process: is the innovative intervention t1 
more “cost-effective” than the standard intervention t0?. Methods: BCEA provides a 
set of functions that can be used to produce a standardised analysis, by synthesising 
the decision process given the current evidence and uncertainty, as well as producing 
several indicators that can be used to perform Probabilistic Sensitivity Analysis (PSA) 
to parameter and model structure uncertainty. These include the Cost-Effectiveness 
Acceptability Curve and the analysis of the Expected Value of Information, which can 
be used to prioritize research. Results: BCEA uses as inputs vectors of simulations 
from the distributions of the average costs and benefits. This naturally fits the Bayesian 
framework, but a frequentist analysis can also be carried out by using tools such as 
the bootstrap. There is scope for linking R and programs such as Excel to facilitate a 
comprehensive health economic analysis, including extensive PSA. ConClusions: 
In this talk, I will present the main feature of BCEA and its applicability to the wider 
context of health economic evaluation and cost-effectiveness analysis.
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objeCtives: Budget impact models (BIMs) which demonstrate the economic impact 
of introducing or increasing the use of specific treatments are routinely used to assist 
the NHS with financial planning. A core component of any BIM is the estimation 
of the eligible patient population. The objective of this study was to identify an 
appropriate methodology for estimating the size of the stage IIIb/IV EGFR M+ non-
small cell lung cancer (NSCLC) patient population eligible for first-line treatment 
with a tyrosine kinase inhibitor such as afatinib (GIOTRIF®). Methods: A review 
of the approach taken by NICE in the costing statements of all treatment options 
for patients with advanced (stage IIIb) or metastatic (stage IV) EGFR M+ NSCLC was 
conducted. The costing statements of tyrosine kinase inhibitors afatinib, erlotinib 
and gefitinib were reviewed, as was the costing statement for the chemotherapy 
agent pemetrexed. Results: Based on the reviewed approaches, the calculation can 
be broken down into six discrete steps from the estimation of the general popula-
tion to the target population: (1) Incidence of lung cancer; (2) Proportion of NSCLC; 
(3) Proportion with stage IIIb/IV NSCLC; (4) Proportion who receive first-line chemo-
therapy; (5) Proportion with EGFR mutation status; and (6) Proportion who are EGFR 
M+. A detailed breakdown of the methods used to calculate the patient population 
eligible for treatment with afatinib was not available in the respective NICE costing 
statement; however the eligible population estimated by NICE validates that this 
approach is reasonable. ConClusions: The methodology employed by NICE to 
estimate the proportion of stage IIIb/IV EGFR M+ NSCLC patients was broadly con-
sistent across all costing statements considered. Is it reasonable to assume that this 
approach, used to estimate the population of stage IIIb/IV EGFR M+ NSCLC patients 
in England and Wales is also applicable in Scotland and Ireland.
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ARe cARe-SeekeRS good cAndidAteS foR SubgRouPS coSt-effectiveneSS 
AnAlySeS?
Rapp T.1, Sirven N.2
1University of Paris Descartes, Paris, France, 2Université Paris Descartes, Paris, France
objeCtives: There is a growing need to consider heterogeneity in cost-effectiveness 
analyses (CEA). To capture heterogeneity, subgroups analyses have been performed 
using various socio-demographic and clinical variables. However, the results of these 
subgroups CEA can be considered inequitable. Consequently, there is need to find new 
subgroups that can be used for decision-making. Methods: We explore whether 
subgroups defined by care-seeking behaviors are good candidates for CEA subgroup 
analysis. Care-seekers are defined as patients who received both an early diagnosis 
and an early treatment. We use data from the PLASA study, a French randomized 
controlled trial designed to reduce the rate of functional decline in Alzheimer’s 
disease: 1,131 patients were randomized in an intervention group and in a control 
group and were followed during a 2-year period. We use a sample selection model to 
explore whether the unobserved heterogeneity associated with the early diagnosis 
decision is correlated with the unobserved heterogeneity associated with the early 
treatment decision. We use a fixed-effect model to explore whether the rate of func-
tional decline was lower within the care-seekers subgroup. Results: Our theoreti-
cally grounded selection model shows that the care-seeking behavior is associated 
with unobserved preferences, motivating the need to run subgroup analyses within 
a subgroup of care-seekers. Our fixed-effect model results show that on average, 
the clinical intervention was not effective. However, the intervention was effective 
within the subgroup of care-seekers. Care-seekers who received the intervention did 
not face a significant decline in their functional status over the 2-year study period. 
On the contrary, care-seekers in the control group lost on average 9 points of ADCS-
ADL per year (p< 0.01). ConClusions: Stratifying CEAs by care-seekers subgroups 
seems relevant. Our analyses can be easily implemented by adding three questions 
in the clinical protocol.
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objeCtives: To identify groups of countries with similar health prefer-
ences. Methods: Cluster analyses were performed for the 242 states of the gen-
eral population EQ-5D valuations for 13 published studies based on Time Trade 
Off; and for 10 studies based on the Visual Analogue Scale. The perfect health state 
was not included. Cluster and their optimal number were identified by means of 
the Ward algorithm with the Euclidean measure and the hierarchical clustering 
technique. The identified clusters in each case are compared in order to find out 
whether they coincide. Results: 3 clusters were identified for TTO: 1) Germany, 
Argentina, Poland, The Netherlands, Denmark; 2) Japan, South Korea, USA, Hispanic 
USA, Zimbabwe; 3) Spain, Chile, UK. 4 clusters were identified for VAS: 1) Belgium, 
New Zealand, Germany; 2) Europe, UK, Spain; 3) Denmark, Slovenia; 4) Finland, 
Argentina. Countries are not in the same clusters for the two methodologies. Only 
the UK and Spain belong in the same groups in both cases. ConClusions: Health-
state valuations tend to be clustered in a few groups of countries but the groups 
differ according to the methodology. This suggests that Visual Analogue Scale results 
may not be a good approximation to Time Trade Off.
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objeCtives: Productivity costs often reflect a large part of the total cost in eco-
nomic evaluations adopting a societal perspective. Currently, no consensus exists 
on how productivity losses are best measured. We aimed to develop a standardized 
instrument for measuring productivity losses to enhance the comparability and gen-
eralizability of the outcomes of economic evaluations. Methods: A focus group 
of well-experienced researchers in the field of measuring and valuing productivity 
losses for use in economic evaluations assessed the instruments’ main quality criteria 
including: building on pre-knowledge and evidence on items’ reliability and valid-
ity, inclusion of all relevant domains of productivity losses, allowing for quantifying 
productivity losses suitable for self-report. A feasibility study was performed to check 
on consistency and intelligibility of the questionnaire and applicability for different 
valuation methods. Results: The focus group identified three separate aspects of 
productivity losses leading to three modules in the iPCQ. Questions for measuring 
absenteeism and presenteeism are evidence- based originating from the Short-Form 
Health & Labour Questionnaire and PRODISQ. As evidence regarding measurement of 
losses of unpaid work is lacking, the questions of this module were developed during 
brainstorm sessions, based on similar questions on paid work. To enhance the instru-
ments’ feasibility and responsiveness the draft version was translated into language 
level 1 by an agency specialized in language and clear writing. The feasibility study 
included 195 respondents aged > 18 years. Five percent identified problems while 
filling in the iPCQ, including the questionnaire’s instructions and routing (n= 8) and 
wording (n= 2). ConClusions: The iPCQ is based on previously available instruments 
and satisfies the current scientific state of play in productivity cost measurement 
and valuation. The instrument is understandable for the vast majority of the general 
public including low-educated people. To enhance the applicability of the iPCQ for 
national and international studies a translation in English is performed.
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objeCtives: There is a growing need for early evaluation of innovative technologies 
to prevent ineffective and expensive technologies to be widely diffused in health 
care. The headroom method was introduced for early determination of the potential 
value of new technologies. In this study we explore the feasibility and usefulness of 
the headroom method in the early assessment of diagnostic technologies with no 
immediate treatment implications. Methods: We applied the headroom method 
to the implementation of whole exome sequencing (WES) into the current diagnostic 
trajectory of complex pediatric neurology. We determined the room for improvement 
regarding health-related quality of life (HRQoL), diagnostic yield and the duration of 
the current diagnostic trajectory. Results: The headroom in a certain diagnostic 
trajectory can be calculated after the so-called effectiveness gap is established and 
monetised. The preferred measure for the effectiveness gap is HRQoL expressed in 
quality-adjusted life years (QALYs). Since the direct product of diagnostics is informa-
tion, and not improved health, no impact on HRQoL is expected. Other measures, such 
as diagnostic yield, can also be used to calculate the effectiveness gap. Unlike QALYs, 
these appeared difficult to monetise, however. Despite this difficulty, effectiveness gap 
calculation using these effect measures is very informative on the room for improve-
ment in current clinical practice. In combination with foreseeable downstream costs 
and savings due to a new technology it gives an idea of the potential societal value of 
this technology. ConClusions: Despite some methodological challenges, the head-
room method proved to be potentially useful in early health economic evaluation of 
diagnostic technologies with no immediate treatment implications.
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objeCtives: BCEA is a R library specifically designed to post-process the result of a 
health economic model. Typically, this consists in the estimation of a set of relevant 
